Pfizer Says Braftovi Combination Regimen Improves Response Rate in Metastatic Colorectal Cancer

MT Newswires Live01-12

Pfizer (PFE) said Saturday data from a randomized cohort showed its braftovi combination regimen with cetuximab and folfiri showed improved objective response rates in patients with previously untreated metastatic colorectal cancer with a BRAF V600E mutation.

Treatment with the braftovi combination regimen achieved a confirmed objective response rate of 64.4%, compared with 39.2% for standard-of-care folfiri with or without bevacizumab, the company said.

Pfizer said responses with the braftovi combination were more durable, with 57.4% of patients maintaining a response lasting 6 months or longer.

The safety profile of braftovi in combination with cetuximab and folfiri was consistent with known profiles of each individual agents, and no new safety signals were identified, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment